Bronchogen
also known as Ala-Glu-Asp-Leu, AEDL
Ala-Glu-Asp-Leu tetrapeptide developed within the Khavinson bioregulator tradition. Demonstrated bronchopulmonary tissue regeneration in rat COPD models, restoring ciliated epithelium, normalizing secretory IgA, and reducing neutrophilic inflammation. Administered at 0.05 ng/mL in organotypic culture, the peptide showed tissue-specific stimulation of bronchial explants in both young and aged rats.
At a glance
Research models: tissue culture / parenteral
Primary target — Bronchial epithelial cells [kuzubova-2015].
Pathway — Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration.
Downstream effect — Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B production [kuzubova-2015][titova-2017].
Origin — Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework.
| Parameter | Value |
|---|---|
| Effective concentration (culture) | 0.05 ng/mL [zakutski-2006]Demonstrated in organotypic tissue culture of bronchial explants. |
| Treatment duration (animal) | 1 month (30 days) [kuzubova-2015][titova-2017]Course duration in rat COPD models. |
| Evidence basis | Animal models (rat) / organotypic culture [titova-2017][kuzubova-2015][zakutski-2006]No human clinical trials reported in available literature. |
| Model system | NO₂-induced COPD (60-day intermittent exposure) [titova-2017] |
| Tissue specificity | Selective for bronchopulmonary tissuePart of Khavinson organ-specific bioregulator series. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- 01Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
- 02Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts. [titova-2017][kuzubova-2015]
- 03Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation. [zakutski-2006]
- 04Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Sources
of 35 rendered claims carry a resolvable citation.
- [kuzubova-2015]Kuzubova 2015 — Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.
journal, 2015 - [titova-2017]Titova 2017 — [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY].
journal, 2017 - [zakutski-2006]Zakutskiĭ 2006 — [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
journal, 2006